Menu

Another NFL Victim of Brain Trauma?

Former NFL linebacker Junior Seau commits suicide. Is head injury-induced dementia to blame?

May 3, 2012
Jef Akst

Junior SeauWIKIMEDIA COMMONS, JJ HALL

Former Pro Bowl linebacker Junior Seau died yesterday (May 2) from what police are calling a self-inflicted gunshot wound to the chest. The tragedy makes Seau, who played for the San Diego Chargers, Miami Dolphins, and New England Patriots during his career, the third former-NFL player to commit suicide in the last 15 months. Speculation is swirling that Seau's death, like the other two suicides, might all be linked to the head injuries the players enduring during their years on the football field.

Former Atlanta Falcon Ray Easterling and former Chicago Bear Dave Duerson also shot themselves recently, and both were suspected to have symptoms of dementia. Duerson even requested that his brain be used for research, and after his death, researchers at the Boston University School of Medicine examine his brain and found evidence of a neurodegenerative disease linked to concussions, called chronic traumatic encephalopathy (CTE). However, while Seau’s ex-wife Gina told The Associated Press that he sustained concussions during his career, it’s still unclear whether he suffered similar symptoms or if his suicide is related to the head trauma.

"We have no clues whatsoever," Gina Seau told ABC News. "We're as stunned and shocked as anyone else. We're horribly saddened. We miss him and we'll always love him."

If Seau was suffering, he wouldn’t be alone. “Thirty percent of our 116 players have major depression secondary to brain injuries,” Daniel Amen, founder of Amen Clinics, Inc., a company that's measuring blood flow and electrical activity in the brains of active and retired NFL players, told The Scientist. “These players do not know that is help is available to them…. With the right help there is great hope for them.”

Read more about CTE and its potential link to football-induced head trauma in “Punch Drunk,” The Scientist, December 2011.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.